Clinical Trial Update: Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial investigates combining NKG2D CAR-NK cell therapy with a PD-1 monoclonal antibody to treat anaplastic thyroid carcinoma. The study is in Phas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma

Drugs mentioned

• NKG2D CAR-NK (CAR-NK cell therapy targeting NKG2D ligands)
• PD-1 monoclonal antibody

Snippet

Sponsor: Zhejiang Provincial People's Hospital | Conditions: Anaplastic Throid Carcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING